Tìm theo
Regadenoson
Các tên gọi khác (1) :
  • Lexiscan
diagnostic agents
Thuốc Gốc
Small Molecule
CAS: 313348-27-5
ATC: C01EB21
CTHH: C15H18N8O5
PTK: 390.354
Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C15H18N8O5
Phân tử khối
390.354
Monoisotopic mass
390.140015726
InChI
InChI=1S/C15H18N8O5/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21)/t7-,9-,10-,14-/m1/s1
InChI Key
InChIKey=LZPZPHGJDAGEJZ-AKAIJSEGSA-N
IUPAC Name
1-{6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-9H-purin-2-yl}-N-methyl-1H-pyrazole-4-carboxamide
Traditional IUPAC Name
1-{6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl}-N-methylpyrazole-4-carboxamide
SMILES
CNC(=O)C1=CN(N=C1)C1=NC2=C(N=CN2[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C(N)=N1
Độ hòa tan
4.85e+00 g/l
logP
-2.3
logS
-1.9
pKa (strongest acidic)
12.37
pKa (Strongest Basic)
1.63
PSA
186.46 Å2
Refractivity
95.48 m3·mol-1
Polarizability
37.48 Å3
Rotatable Bond Count
4
H Bond Acceptor Count
10
H Bond Donor Count
5
Physiological Charge
0
Number of Rings
4
Bioavailability
1
Rule of Five
true
Dược Lực Học : Regadenoson rapidly increases coronary blood flow (CBF) which is sustained for a short duration. Mean average peak velocity increased to greater than twice baseline by 30 seconds and decreased to less than twice the baseline level within 10 minutes. Myocardial uptake of the radiopharmaceutical is proportional to (CBF). Regadenoson increases blood flow in normal coronary arteries but not in stenotic (blocked) arteries. The significance of this finding is that stenotic arteries will take up less of the radiopharmaceutical than normal coronary arteries, resulting in a signal that is less intense in these areas.
Cơ Chế Tác Dụng : Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008. Regadenoson is an selective low-affinity (Ki= 1.3 µM) A2A receptor agonist that mimics the effects of adenosine in causing coronary vasodilatation and increasing myocardial blood flow. It is a very weak agonist of the A1 adenosine receptor (Ki > 16.5 µM). Furthermore, it has negligible affinity to A2B and A3 adenosine receptors. Regadenoson is undergoing trials for use in pharmacological stress tests. Adenosine slows conduction time through the A-V node, can interrupt the reentry pathways through the A-V node, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT), including PSVT associated with Wolff-Parkinson-White Syndrome.
Dược Động Học :
▧ Absorption :
The pharmacokinetic profile of regadenoson is best described by a 3-compartment model. T max, injection = 1 to 3 minutes; Onset of pharmacodynamic response = 1 to 3 minutes; E max 12.3 ng/mL
▧ Volume of Distribution :
Central compartment: 11.5 L; Steady state: 78.7 L
▧ Metabolism :
The metabolism of regadenoson is unknown in humans. The cytochrome P450 enzyme system is not likely to be involved with the metabolism of regadenoson.
▧ Route of Elimination :
58% of total regadenoson eliminate is via renal excretion
▧ Half Life :
Initial phase: 2-4 minutes; Intermediate phase: 30 minutes (this phase coincides with a loss of the pharmacodynamic effect); Terminal phase: 2 hours
▧ Clearance :
Average plasma renal clearance = 450 mL/min. As this value is larger than the glomerular filtration rate, this suggests occurrence of renal tubular secretion.
Độc Tính : The most common (incidence ≥ 5%) adverse reactions to regadenoson are dyspnea, headache, flushing, chest discomfort, dizziness, angina pectoris, chest pain, and nausea. MTD (male, supine position): 20 µg/kg; MTD (male, standing position): 10 µg/kg;
Chỉ Định : Diagnostic agent for radionuclide myocardial perfusion imaging (MPI)
Tương Tác Thuốc :
  • Aminophylline Reduces duration of >2-fold increase in peak flow velocity. No effect on heart rate increase.
  • Caffeine Caffeine may diminish the vasodilatory effect of Regadenoson. Regadenoson prescribing information recommends avoiding using caffeine or other methylxanthine containing products (e.g., theophylline) for at least 12 hours prior the the administration of regadenoson. The impact of low doses of caffeine-containing products such as coffee, tea, and colas is unclear.
  • Dipyridamole Dipyridamole may change the effects of regadenoson. When possible, withhold dipyridamole for at least two days prior to regadenoson administration.
  • Theophylline Non-specific adenosine receptor antagonist may interfere with the vasodilation activity of regadenoson. Avoid methylxanthines for at least 12 hours before administration of regadenoson.
Liều Lượng & Cách Dùng : Solution - Intravenous - 0.4mg/5 mL
Dữ Kiện Thương Mại
Nhà Sản Xuất
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB06213
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=219024
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=47207372
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D05711
ChemSpider
http://www.chemspider.com/Chemical-Structure.189859.html
BindingDB
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50119132
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0469-6501-89
Wikipedia
http://en.wikipedia.org/wiki/Regadenoson
RxList
http://www.rxlist.com/cgi/generic/lexiscan.htm
PDRhealth
http://www.pdrhealth.com/drugs/lexiscan
Drugs.com
http://www.drugs.com/ppa/regadenoson.html
... loading
... loading